The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib

Leukemia. 2024 Sep;38(9):2041-2045. doi: 10.1038/s41375-024-02314-7. Epub 2024 Jun 15.

Authors

Inga B Leske¹, Oliver Hantschel²

Affiliations

¹ Institute of Physiological Chemistry, Faculty of Medicine, Philipps University of Marburg, 35032, Marburg, Germany.
² Institute of Physiological Chemistry, Faculty of Medicine, Philipps University of Marburg, 35032, Marburg, Germany. [email protected].

No abstract available

Publication types

Letter

MeSH terms

Drug Resistance, Neoplasm* / genetics
Fusion Proteins, bcr-abl* / genetics
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Niacinamide / analogs & derivatives
Protein Isoforms* / genetics
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use
Proto-Oncogene Proteins c-abl / genetics
Proto-Oncogene Proteins c-abl / metabolism
Pyrazoles

Substances

Fusion Proteins, bcr-abl
asciminib
Protein Isoforms
Protein Kinase Inhibitors
ABL1 protein, human
Proto-Oncogene Proteins c-abl
Niacinamide
Pyrazoles